Blood Changes During Electroconvulsive Therapy for Depression
Measures blood metabolite changes during electroconvulsive therapy in adults with major depression.
Plain-language title generated from the registry record
Registry title: Metabolomics During ElectroConvulsivoTherapy
Key facts
- Where
- Bron, FranceSee the site
Where in France
- Centre Hospitalier Le VinatierBron, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hôpital le Vinatier
- Trial code
- NCT05973643
- Record updated
- 24 July 2025
- Original description
Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.Read full original descriptionShow less
Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode
Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.
Inclusion: Major depressive episode according to DSM-5 criteria; Diagnosis of major depressive disorder or bipolar disorder; MADRS score >22; having given written, free and informed consent; without protective measures; resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks; current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure.
Exclusion: suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5; Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder; suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and/or neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5; whose consent is not admissible or who refuse to participate in the study; deprived of liberty by judicial or administrative decision; For which there is a particular risk contraindicating the cure of ECT.